Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application
Zumutor Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Novel NK cell Therapeutics ZM008 Against Locally Advanced or Metastatic Solid Tumors - FDA provides very specific recommendation for the proposed ZM008 program - Company intends to submit an IND application for ZM008 this year against locally advanced or metastatic solid tumours [...]